CA
NZ
UK
AU
IND
US
● No company-specific news was found to explain the move.
● Third-quarter net sales climbed sharply from a year earlier.
● An independent monitoring committee advised it was unlikely to succeed.
● Results are expected later this quarter.
● No company-specific news was cited for the pullback.
● The price target was lowered to $15 from $40.
● A separate preview said the company raised its full-year outlook.
● The move came in extended trading after the regular session.
● The move came ahead of upcoming lung-cancer data.
● Adjusted EBITDA guidance was also raised.
Please wait processing your request...